Vericel CorpVCEL
About: Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Employees: 357
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 3 (+2) [Q4]
50% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 30
33% more capital invested
Capital invested by funds: $2.15B [Q3] → $2.86B (+$715M) [Q4]
23% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 82
4% more funds holding
Funds holding: 264 [Q3] → 274 (+10) [Q4]
2.8% more ownership
Funds ownership: 104.48% [Q3] → 107.28% (+2.8%) [Q4]
16% less call options, than puts
Call options by funds: $6.28M | Put options by funds: $7.49M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Truist Securities Richard Newitter 57% 1-year accuracy 29 / 51 met price target | 34%upside $51 | Buy Maintained | 11 Apr 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 57 / 190 met price target | 58%upside $60 | Buy Reiterated | 28 Feb 2025 |
Canaccord Genuity Caitlin Cronin 21% 1-year accuracy 3 / 14 met price target | 76%upside $67 | Buy Maintained | 3 Feb 2025 |
Financial journalist opinion









